Clinical trial · no report yet · Phase 1/Phase 2
LiDer
Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer
- NCT06385548 ↗
- Withdrawn
- Vall d'Hebron Institute of Oncology
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| YouTube | 2 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- Phase I-II Study to Evaluate the Safety, Tolerability, and Efficacy of Lurbinectedin and Dostarlimab in Patients with Advanced/Recurrent Endometrial Cancer with Disease Progression Following Previous Platinum Chemotherapy Therapy
- Phase
- Phase 1/Phase 2
- Status
- Withdrawn
- Conditions
- Endometrial Cancer
- Interventions
- Lurbinectedin; Dostarlimab
- Arms
- Lurbinectedin and Dostarlimab Combination Therapy · Experimental
- Enrollment
- 0
- Primary outcomes
- Maximum Tolerated Dose (MTD) and Recommended Dose (RD) Determination
- Evaluation of Lurbinectedin and Dostarlimab Combination Therapy in Advanced/Recurrent Cervical Cancer Patients
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- May 2024 (estimated)
- Primary completion
- May 1, 2024
- Results posted
- No
- Registry record
- NCT06385548 · updated Apr 1, 2025